| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/29/2024 | $25.00 | Buy | Alliance Global Partners |
| 7/19/2024 | $22.00 | Buy | Canaccord Genuity |
| 10/9/2023 | $25.00 | Buy | H.C. Wainwright |
| 7/19/2023 | $30.00 | Buy | Canaccord Genuity |
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
3/A - Cibus, Inc. (0001705843) (Issuer)
3 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4 - Cibus, Inc. (0001705843) (Issuer)
4/A - Cibus, Inc. (0001705843) (Issuer)
Alliance Global Partners initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00
Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $22.00
H.C. Wainwright initiated coverage of Cibus Global with a rating of Buy and set a new price target of $25.00
Canaccord Genuity resumed coverage of Cibus Global with a rating of Buy and set a new price target of $30.00
Canaccord Genuity analyst Austin Moeller assumes Cibus (NASDAQ:CBUS) with a Buy rating and announces Price Target of $22.
Strengthens Portfolio in Pod Shatter Reduction, Herbicide Tolerances, High Fiber Wheat, and Improved Quality Alfalfa; Covers Europe, Asia, Latin America, Canada, and the U.S.
On Wednesday, Cibus Inc (NASDAQ:CBUS) announced that it has expanded its intellectual property coverage for ten gene editing and trait families. Over the last six months, intellectual property expansion has covered several areas, including gene editing, productivity traits, and quality traits, like high-fiber wheat. This strengthens the company’s patent coverage in geographies including, but not limited to, Europe, Asia, Latin America, Canada, and the U.S. Cibus is focused on developing complex gene-edited traits in plants, such as Pod Shatter Reduction in Canola and Herbicide Tolerance in Rice. The company’s plant trait intellectual property is developed using its Rapid Trait De
Shares of Core & Main Inc (NYSE:CNM) fell sharply during Tuesday's session after the company reported mixed first-quarter financial results. Core & Main posted quarterly earnings of 49 cents per share, missing market expectations of 52 cents per share. The company's quarterly sales came in at $1.74 billion versus estimates of $1.72 billion, according to data from Benzinga Pro. Core & Main shares dipped 11.4% to $49.77 on Tuesday. Here are some other stocks moving in today’s mid-day session. Gainers MicroAlgo Inc (NASDAQ:MLGO) shares jumped 284% to 5.99 after the company announced that it will jointly establish a micro-consciousness quantum research center with WiMi. Sobr S
HC Wainwright & Co. analyst Amit Dayal reiterates Cibus (NASDAQ:CBUS) with a Buy and maintains $25 price target.
Cibus (NASDAQ:CBUS) reported quarterly losses of $(1.12) per share. This is a 79.49 percent increase over losses of $(5.46) per share from the same period last year. The company reported $545.000 thousand in sales this quarter. This is a 1.20K percent increase over sales of $42.000 thousand the same period last year.
Cibus and Biographica to collaborate on identifying gene editing targets for Cibus' disease resistance trait development Biographica's proprietary AI platform linked with Cibus' crop editing abilities provide opportunities for discovery and commercial application SAN DIEGO and LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, and Biographica, a UK-based leader in AI and graph machine learning for gene discovery, are pleased to announce a collaborative pilot project focused on advancing disease resistance in oilseed rape and Canola. This partnership
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, will participate in the 13th Annual Roth Technology Conference. The conference is being held in New York City on November 19-20, 2024. Cibus is available for meetings on both days of the conference. Conference attendees should reach out to the Company or their conference host representative to schedule. About Cibus Cibus is a leading independent plant trait company that develops and licenses plant traits
Cibus has successfully made the edits in Canola associated with the Company's 4th mode of action for its White Mold (Sclerotinia) trait Builds upon Cibus' progress with its Sclerotinia resistance trait in Canola after Field Trial results for its 2nd mode of action showed enhanced disease resistance SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that it has successfully completed edits in Canola for its 4th mode of action for its Sclerotinia resistance trait and expects greenhouse results in the first quarter of 2025.
Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development Great progress in Rice as we execute on our agreements with four major seed company customers in the United States and Latin America, with germplasm received from all customers; completed successful field trials with HT3 in customer germplasm, as well as completed what the Company believes to be the first field trials for stacked gene-edited herbicide tolerance traits Also in Rice, signed an Agreement with RTDC Corporatio
The greenhouse results represent an important success milestone in the development of its second-generation of HT2 edited Canola Cibus expects to initiate seed bulk up for testing in fields in 2025 SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that its next generation edits for herbicide tolerance (HT2) in Canola have shown increased tolerance to the herbicide in greenhouse testing. With the achievement of this milestone, seed from these edited plants will be utilized to initiate larger scale field testing in the 2025 season. Reachi
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2024 Results Conference Call Event Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317-6026 (International) Event Link: https:/
SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, announced a restructuring and cost reduction initiatives, including a reduction in force ("RIF"), to optimize the Company's business and cost structure in alignment with its strategic priority to advance its nearest-term commercial opportunities. The Company expects these actions, along with other initiatives, to generate cost savings of approximately $10 million on an annualized run-rate basis. When these and other initiatives are fully implemented by early 2025, the Company expects them
SAN DIEGO, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, has been named a finalist for the Euroseeds2024 InnovActor Award and will have its technology showcased on the InnovAction Stage at the Euroseeds2024 Congress. Cibus' presentation will be given by Dr. Jim Radtke (SVP Product Development) who was recently honored by the American Seed Trade Association (ASTA) with a Lifetime Achievement Award. The event will take place in Copenhagen, Denmark, October 13-16 with the winner named at the 2024 InnovActor Ceremony on October 15. "Innovation plays a crucial role in
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops plant traits to license to seed companies for royalties, today announced that Peter Beetham, Co-Founder, President and Chief Operating Officer, will participate in a panel discussion titled "Sowing Solutions: Innovations in Climate-Resilient Seeds" at the Food+ Forum during the 79th session of the United Nations General Assembly ("UNGA") in New York, NY, on Thursday, September 26, at 12:50 pm ET. "As a leader in the gene editing industry, Cibus is enabling the agriculture industry's efforts to address the ramifications of climate change for the benefit of our gl
SAN DIEGO, Sept. 18, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company" or "Cibus"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced the pricing of an underwritten public offering of 3,000,000 shares of its Class A Common Stock, par value $0.0001 per share ("Class A Common Stock") at a public offering price of $4.00 per share. The Company has granted the underwriters a 45-day option to purchase an additional 450,000 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the offering are
8-K - Cibus, Inc. (0001705843) (Filer)
10-Q - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
424B5 - Cibus, Inc. (0001705843) (Filer)
8-K - Cibus, Inc. (0001705843) (Filer)
Cibus Announces Election of New Board Member, Deepening Strategic Leadership and Experience SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in Gene Editing in agriculture and the development of Productivity Traits in plants that directly impact farming productivity and profitability announced that its Board of Directors has elected Jim Collins, former CEO of Corteva, to the Board. "Jim brings to Cibus immense knowledge and strategic vision on the direction of the future role and use of Gene Editing in agriculture," said Mark Finn, Chair of the Audit Committee. "Jim's experience leading one of the largest agricultural and seed companies will gi
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, announced today the appointment of Steve Berreth as General Counsel and Corporate Secretary for the corporation. Mr. Berreth was previously Vice President, General Counsel and Secretary for Syngenta Crop Protection LLC, the North American Subsidiary of Syngenta AG, one of the world's largest biotechnology agribusinesses and one of the largest crop protection chemical and seed businesses in the world. He was a member of the Syngenta global legal and compliance leadership teams and led the North American le
Announced a strategic realignment to advance commercial opportunities, focusing resources on advancement of weed management platform (HT1 and HT3) for Rice, Pod Shatter Reduction in Canola, Sclerotinia resistance for Canola and Soybean, and on Soybean platform development Great progress in Rice as we execute on our agreements with four major seed company customers in the United States and Latin America, with germplasm received from all customers; completed successful field trials with HT3 in customer germplasm, as well as completed what the Company believes to be the first field trials for stacked gene-edited herbicide tolerance traits Also in Rice, signed an Agreement with RTDC Corporatio
SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report third quarter 2024 financial results on Thursday, November 7, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2024 Results Conference Call Event Date: Thursday, November 7, 2024 Time: 4:30 p.m. ET Participant Numbers: +1-877-300-8521 (U.S.), +1-412-317-6026 (International) Event Link: https:/
Demonstrated continued momentum securing an agreement for its Herbicide Tolerance (HT) traits in Rice with a fourth customer in the second quarter with signing of agreement with Federacion Nacional de Arroceros ("FEDEARROZ"); builds on prior agreements with Loveland Products, Inc., a subsidiary of Nutrien, Ltd., in the United States and with Interoc S.A. in Latin America Rice platform is the Company's first entry into the major global grain crops with significant potential commercial opportunities Wheat platform operational, enables Cibus access into the largest global grain crop in planted acres Continued achievement of milestones in the development of its Advanced Trai
SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies for royalties, today announced that the company will report second quarter 2024 financial results on Thursday, August 8, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Second Quarter 2024 Results Conference Call Event Date: Thursday, August 8, 2024 Time: 4:30 p.m. ET Participant Numbers: +1-800-343-5172 (U.S.), +1-203-518-9856 (International)The conference ID "CIBUS" or 2
Important EU Parliament vote on gene editing continues global momentum for the approval of new genomic techniques (NGTs) as similar to conventional breeding Completed single cell regeneration platform for Wheat – with Canola & Rice, Cibus now has its semi-automated crop platform operational for 3 of the top 5 major crops Signed three agreements in Rice including with Loveland Products Inc., a subsidiary of Nutrien Ltd., and Interoc S.A., for Cibus' two proprietary Herbicide Tolerance traits (HT1 and HT3) Continued progress with customers toward commercializing Pod Shatter Reduction (PSR) trait in Canola Continues to demonstrate commercial-level trait performance following successful seas
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. First Quarter 2024 Results Conference Call Event Date: Thursday, May 9, 2024 Time: 4:30 p.m. ET Participant Numbers: +1-877-704-4453 (U.S.), +1-201-389-0920
SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report fourth quarter 2023 financial results on Thursday, March 21, 2024. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Fourth Quarter 2023 Results Conference Call Event Date: Thursday, March 21, 2024Time: 4:30 p.m. ETParticipant Numbers: +1-877-704-4453 (U.S.), +1-201-389-0920 (Internation
During the 2023 field season, Cibus completed extensive field trials for its three developed traits, PSR in canola and HT1 and HT3 in rice. Company also reports continued progress of Cibus' high-throughput soybean editing system and its two advanced traits for Sclerotinia resistance and HT2. Initial UK field trials for its PSR trait in WOSR are underway in conjunction with positive tailwinds in European regulatory progress; accelerating Cibus' PSR trait in the European market. Launched strategic realignment and cost savings initiatives to direct focus towards advancing late-stage activities, aligning with its primary commercial objectives. Management to host a conference call webcast Thu
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a global leader in gene editing in agriculture and the development of productivity traits in plants, today announced that the Company will report third quarter 2023 financial results on Thursday, November 9, 2023. Cibus' management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: Cibus, Inc. Third Quarter 2023 Results Conference CallEvent Date: Thursday, November 9, 2023Time: 4:30 p.m. ETParticipant Numbers: +1-877-243-8548 (U.S.), +1-312-281-2974 (International)Event Link: https://investor.cibus.com/events For interested
Two gene editing pioneers closed merger to create a leading agricultural gene editing company with an expanded portfolio of patents, patents pending, and exclusive licenses to core technologies for gene editing of plants. Important greenhouse data continues to show promising results for Cibus' first disease resistance trait for Sclerotinia resistance. Begins commercialization process for its three developed traits with initial transfers to customers: pod shatter reduction in canola and HT1 and HT3 in rice. Opens first stand-alone high-throughput (gene editing) breeding facility for trait production to support the commercial launch of its first three developed traits across can